| | First author | Year | Ethnicity (country) | Case number | Median age | Disease stage | Follow-up time | Treatment line | Chemotherapy | Outcomes | Genotyping method | SNPs (allele frequency) |
| | Zhou [34] | 2004 | Caucasian (USA) | 128 | 60 (32–78) | III-IV | 65.3 (4.9–121.5) | 1st/2nd | Platinum-based | OS | PCR-RFLP | rs11615 (T: 0.60), rs3212986 (A: 0.32) | | Isla [11] | 2004 | Caucasian (Spain) | 62 | 62 (35–78) | IIIB-IV | 13.5 (8–19) | 1st | Cisplatin/docetaxel | ORR, OS, PFS | TaqMan PCR | rs11615 (T: 0.55) | | Ryu [12] | 2004 | Asian (Korea) | 109 | 60 (32–78) | IIIB-IV | NR | 1st | Cisplatin based | ORR | SNaPShot assay | rs11615 (T: 0.28) | | Yuan [43] | 2005 | Asian (China) | 200 | 56 (30–74) | IIIB-IV | NR | 1st | Cis or carboplatin | ORR | PCR-RFLP | rs3212986 (A: 0.26) | |
de las Peñas [36] | 2006 | Caucasian (Spain) | 135 | 62 (31–81) | IIIB-IV | 9.7 (0.4–30.7) | 1st | Cisplatin/gemcitabine | OS, PFS | TaqMan PCR | rs11615 (T: 0.57) | | Park [35] | 2006 | Asian (Korea) | 245 | 67 (28–92) | III-IV | NR | 1st | Cisplatin based | OS | SNaPShot assay | rs11615 (T: 0.24) | | Su [13] | 2007 | Asian (China) | 76 | 58 (28–80) | III-IV | NR | 1st | Platinum-based | ORR | TaqMan PCR | rs11615 (T: 0.25) | | Tibaldi [14] | 2008 | Caucasian (Italy) | 65 | 65 (44–77) | IIIB-IV | NR | 1st | Cisplatin/gemcitabine | ORR, OS, PFS | TaqMan PCR | rs11615 (T: 0.58) | | Kalikaki [15] | 2009 | Caucasian (Greece) | 119 | 61 (39–85) | III-IV | 28.5 (0.4–60) | 1st/2nd | Platinum-based | ORR, OS | PCR-RFLP | rs11615 (T: 0.5), rs3212986 | | Li [16] | 2010 | Asian (China) | 115 | 59.6 | IIIB-IV | NR | 1st | Cis or carboplatin | ORR | 3D polyacrylamide gel-based DNA microarray | rs11615 (T: 0.19), rs3212986 (A: 0.35) | | Shiraishi [17] | 2010 | Asian (Japan) | 640 | 58 (22–78) | IIIB-IV | NR | 1st | Platinum-based | ORR | Pyrosequencing or TaqMan PCR | rs11615 (T: 0.27) | | Chen [18] | 2010 | Asian (China) | 95 | 58 (35–77) | IIIB-IV | NR | NS | Cisplatin based | ORR | Ligase detection reactions | rs11615 (T: 0.26) | | Wang [19] | 2010 | Asian (China) | 90 | 55 (33–73) | IIIB-IV | 9 (3–15) | 1st | Cisplatin based | ORR, PFS | PCR-based sequencing | rs11615 (T: 0.24), rs3212986 (A: 0.35) | | KimCurran [42] | 2011 | Asian (China) | 300 | 60 (33–78) | IIIB-IV | NR | 1st | Cis or carboplatin | ORR, OS | TaqMan PCR | rs3212986 (A: 0.35) | | Okuda [37] | 2011 | Asian (Japan) | 90 | 60 | I–IV | 60 | NS | Cis or carboplatin | OS | PCR-RFLP | rs11615 (T: 0.3), rs3212986 (A: 0.19) | | Ludovini [20] | 2011 | Caucasian (Italy) | 192 | 63 (25–81) | IIIB-IV | 24.6 (14.5–40.8) | 1st | Cisplatin/gemcitabine | ORR | TaqMan PCR | rs11615 (T: 0.44) | |
Viñolas [21] | 2011 | Caucasian (Spain) | 94 | 61 (37–77) | IIIB-IV | NR | 1st | Cisplatin/vinorelbine | ORR | TaqMan PCR | rs11615 (T: 0.59) | | Ren [22] | 2012 | Asian (China) | 340 | 60 (30–78) | IIIB-IV | 18 (8–66) | 1st | Cis or carboplatin | ORR, OS | TaqMan PCR | rs11615 | | Li [23] | 2012 | Asian (China) | 89 | 59 (21–84) | III-IV | NR | NS | Cisplatin based | ORR | TaqMan PCR | rs11615 | | Liao [24] | 2012 | Asian (China) | 62 | 57 (36–78) | IIIB-IV | 22 (4–65) | 1st | Platinum-based | ORR, OS | PCR-RFLP | rs11615 (T: 0.24), rs3212986 (A: 0.40) | | Joerger [25] | 2012 | Caucasian (Holland) | 137 | 59.7 (37–79) | IIIB-IV | 40.00 | 1st | Platinum/gemcitabine | ORR, OS, PFS | TaqMan PCR | rs11615 (T: 0.60) | | Dong [38] | 2012 | Asian (China) | 181 | NR | III-IV | 18.80 | 1st | Platinum-based | OS | Illumina high-throughput genotyping | rs11615 (T: 0.23) | | Krawczyk [26] | 2012 | Caucasian (Poland) | 43 | 63 | IIIB-IV | NR | 1st | Cis or carboplatin | ORR | PCR-RFLP | rs11615 (T: 0.45) | | Cheng [27] | 2012 | Asian (China) | 142 | 62 (43–81) | IIIB-IV | NR | 1st | Cisplatin based | ORR, OS, PFS | AllGlo Probe-based RT-PCR | rs11615 (T: 0.23) | | Zhang [39] | 2012 | Asian (China) | 632 | 62.6 | I–IV | 31.60 | 1st | Cisplatin/gemcitabine | OS | TaqMan PCR | rs11615 (T: 0.59) | | Tiseo [28] | 2013 | Caucasian (Italy) | 49 | 63 (29–79) | IIIB-IV | NR | 1st | Cisplatin based | ORR | TaqMan PCR | rs11615, rs3212986 | | Hong [29] | 2013 | Asian (China) | 135 | 56 (25–72) | IIIB-IV | NR | 1st | Platinum/gemcitabine | ORR, PFS | TaqMan PCR | rs11615 (T: 0.3), rs3212986 (A: 0.34) | | Mlak [40] | 2013 | Caucasian (Poland) | 62 | 61 (38–76) | III-IV | NR | 1st | Platinum/gemcitabine | OS, PFS | PCR-RFLP | rs11615 (T: 0.66) | | Lv [30] | 2014 | Asian (China) | 91 | 59 (34–80) | IIIB-IV | 8 (0.5–13.5) | NS | Cisplatin based | ORR | TaqMan PCR | rs11615 (T: 0.29) | | Sullivan [31] | 2014 | Caucasian (Spain) | 161 | 63.7 (36–85) | III-IV | NR | NS | Cis or carboplatin | ORR | TaqMan PCR | rs11615 (T: 0.66), rs3212986 (A: 0.22) | | Zhao [32] | 2014 | Asian (China) | 192 | 60.8 (26–79) | III-IV | 48 (36–60) | NS | Platinum-based | ORR, OS | MassARRAY Analyzer 4 system | rs11615 (T: 0.36), rs3212986 (A: 0.32) | | Krawczyk [41] | 2014 | Caucasian (Poland) | 115 | 61 | II–IV | 50 (26–74) | 1st | Platinum/pemetrexed | OS, PFS | High Resolution Melt (HRM) | rs11615 (T: 0.61) | | Huang [33] | 2014 | Asian (China) | 187 | 63.8 | III-IV | 39 (27–51) | 1st | Platinum-based | ORR, OS | MassARRAY Analyzer system | rs11615 (T: 0.33), rs3212986 (A: 0.28) |
|
|
